RT Journal Article
SR Electronic
T1 Metabolic Polygenic Risk Scores for Prediction of Obesity, Type 2 Diabetes, and Related Morbidities
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.01.24316620
DO 10.1101/2024.11.01.24316620
A1 Kim, Min Seo
A1 Chen, Qiuli
A1 Sui, Yang
A1 Yang, Xiong
A1 Wang, Shaoqi
A1 Weng, Lu-Chen
A1 Cho, So Mi Jemma
A1 Koyama, Satoshi
A1 Zhu, Xinyu
A1 Yu, Kang
A1 Chen, Xingyu
A1 Zhang, Rufan
A1 Yin, Wanqing
A1 Liao, Shuangqiao
A1 Liu, Zhaoqi
A1 Alkuraya, Fowzan S
A1 Natarajan, Pradeep
A1 Ellinor, Patrick T.
A1 Fahed, Akl C.
A1 Wang, Minxian
YR 2024
UL http://medrxiv.org/content/early/2024/11/04/2024.11.01.24316620.abstract
AB Obesity and type 2 diabetes (T2D) are metabolic diseases with shared pathophysiology. Traditional polygenic risk scores (PRS) have focused on these conditions individually, yet the single disease approach falls short in capturing the full dimension of metabolic dysfunction. We derived biologically enriched metabolic PRS (MetPRS), a composite score that uses multi-ancestry genome-wide association studies of 22 metabolic traits from over 10 million people. MetPRS, optimized to predict obesity (O-MetPRS) and T2D (D-MetPRS), was validated in the UK Biobank (UKB, n=15,000), and tested in UKB hold-out set (n=49,377), then externally tested in 3 cohorts – All of Us (n=245,394), Mass General Brigham (MGB) Biobank (n=53,306), and a King Faisal Specialist Hospital and Research Center cohort (n=6,416). O-MetPRS and D-MetPRS outperformed existing PRSs in predicting obesity and T2D across 6 ancestries (European, African, East Asian, South Asian, Latino/admixed American, and Middle Eastern). O-MetPRS and D-MetPRS also predicted morbidities and downstream complications of obesity and T2D, as well as the use of GLP-1 receptor agonists in contemporary practice. Among 37,329 MGB participants free of T2D and obesity at baseline, those in the top decile of O-MetPRS had a 103% relatively higher chance, and those in the top decile of D-MetPRS had an 80% relatively higher chance of receiving a GLP-1 receptor agonist prescription compared to individuals at the population median of MetPRS. The biologically enriched MetPRS is poised to have an impact across all layers of clinical utility, from predicting morbidities to informing management decisions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementP.N. is supported by grants from the National Institutes of Health (R01HL127564, U01HG011719), P.T.E. is supported by grants from the National Institutes of Health (1R01HL092577, 1R01HL157635, 5R01HL139731), from the American Heart Association Strategically Focused Research Networks (18SFRN34110082), and from the European Union (MAESTRIA 965286). P.N. is supported by grant from National Human Genome Research Institute (U01HG011719). A.C.F. is supported by grants from the National Heart Lung and Blood Institute (K08HL161448 and R01HL164629). Dr. Wang is supported by the Pioneering Action Grants of the Chinese Academy of Sciences. We gratefully acknowledge all participants of UKB, AoU, MGBB and KFSH&RC for their contributions, without whom this research would not have been possible. We also thank the National Institutes of Healths AoU Research Program, the UKB resource, the MGB team and KFSH&RC team, for making available the participant data examined in this study. Further, we acknowledge the dedication and expertise of the research coordinators and the comprehensive Biobank team, whose efforts in participant enrollment and data collection were indispensable.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data are made available from the UK Biobank (https://www. ukbiobank.ac.uk/enable-your-research/apply-for-access) to researchers from universities and other institutions with genuine research inquiries following institutional review board and UK Biobank approval. This research was conducted using the UK Biobank resource under application number 89885. All of Us data are made available from the All of Us Research Study to researchers from universities and other institutions with genuine research inquiries following institutional review board and All of Us approval. KFSH&RC and MGBB data are governed by local laws, so relevant data could be made available by contacting the investigators. The genome-wide association data supporting the findings of this study are publicly available in KoGES (https://koges.leelabsg.org/), Biobank Japan (http://jenger.riken.jp/en/result), FinnGen (https://www.finngen.fi/en/access_results), AGEN T2D (https://kp4cd.org/index.php/node/309), GIANT (https://portals.broadinstitute.org/collaboration/giant/) and Million Veteran Program (via dbGaP at https://ftp.ncbi.nlm.nih.gov/dbgap/studies/, under accession number phs001672). The research was approved by the Beijing Institute of Genomics (Chinese Academy of Sciences) and the China National Center for Bioinformation institutional review board, and the Mass General Brigham institutional review board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data are made available from the UK Biobank (https://www. ukbiobank.ac.uk/enable-your-research/apply-for-access) to researchers from universities and other institutions with genuine research inquiries following institutional review board and UK Biobank approval. This research was conducted using the UK Biobank resource under application number 89885. All of Us data are made available from the All of Us Research Study to researchers from universities and other institutions with genuine research inquiries following institutional review board and All of Us approval. KFSH&RC and MGBB data are governed by local laws, so relevant data could be made available by contacting the investigators. The genome-wide association data supporting the findings of this study are publicly available in KoGES (https://koges.leelabsg.org/), Biobank Japan (http://jenger.riken.jp/en/result), FinnGen (https://www.finngen.fi/en/access_results), AGEN T2D (https://kp4cd.org/index.php/node/309), GIANT (https://portals.broadinstitute.org/collaboration/giant/) and Million Veteran Program (via dbGaP at https://ftp.ncbi.nlm.nih.gov/dbgap/studies/, under accession number phs001672). The research was approved by the Beijing Institute of Genomics (Chinese Academy of Sciences) and the China National Center for Bioinformation institutional review board, and the Mass General Brigham institutional review board.